Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Kringle Pharma, Inc. ( (JP:4884) ) just unveiled an announcement.
Kringle Pharma, Inc. announced that the U.S. FDA has granted orphan drug designation to KP-100IT, a recombinant human hepatocyte growth factor, for treating acute spinal cord injury. This designation provides Kringle Pharma with seven years of market exclusivity in the U.S. upon FDA approval, along with various development incentives. The designation is expected to accelerate drug development in the U.S. and enhance Kringle’s global expansion efforts, potentially impacting partnership discussions with global pharmaceutical companies.
More about Kringle Pharma, Inc.
Kringle Pharma, Inc., established in December 2001 and based in Osaka, Japan, is a late clinical-stage biopharmaceutical company focused on developing novel biologics based on hepatocyte growth factor (HGF). The company is advancing its late-stage pipeline, including oremepermine alfa for acute spinal cord injury and vocal cord scarring, both in Phase 3 clinical trials. Kringle Pharma aims to contribute to global healthcare by developing HGF drugs for patients with incurable diseases.
Average Trading Volume: 78,409
Technical Sentiment Signal: Buy
Current Market Cap: Yen5.87B
See more insights into 4884 stock on TipRanks’ Stock Analysis page.